Nutrition / biomarkers 2020

Ergothioneine and mortality: the Malmö Diet and Cancer cohort, n=3236, 21-year follow-up

The largest human cohort on ergothioneine: participants with higher plasma levels had 15% lower coronary disease risk, 21% lower cardiovascular mortality and 14% lower all-cause mortality over 21 years. Ergothioneine was the metabolite most strongly tied to the healthy-eating pattern.

📄 Where to read the full paper

Smith E. et al. Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. Heart. 2020;106(9):691-697.

Why this study

Ergothioneine is the "mushroom antioxidant" the body hoards via a dedicated transporter, OCTN1. But before this paper no large human cohort had tested whether blood ergothioneine predicts real outcomes rather than just "health benefit" in vitro.

Methods

  • Prospective Malmö Diet and Cancer cohort: 3236 participants free of CVD and diabetes at baseline.
  • 112 plasma metabolites measured by LC-MS; searched for metabolites tied to the "health conscious food pattern" (HCFP).
  • Median follow-up — 21.4 years; endpoints: coronary disease, diabetes, cardiovascular and all-cause mortality.

Findings

Ergothioneine was the metabolite most strongly connected to the healthy-eating pattern — and predicted outcomes (HR per 1 SD increment):

  • Coronary disease: HR 0.85 (−15% risk)
  • Cardiovascular mortality: HR 0.79 (−21%)
  • All-cause mortality: HR 0.86 (−14%)

Limitations

  • Observational — association is not causation; ergothioneine may be a marker of an overall "mushroom/fish/vegetable" diet.
  • The metabolite was measured once at baseline.

Why it matters

This is the fourth branch of ergothioneine on the site: cancer (Ba meta-analysis), MCI (Feng), plasma prediction of cognitive decline (Wu) — and now mortality/CVD (Smith). Malmö's uniqueness — the longest follow-up and largest n of all our ergothioneine cards.